« Return to News | Awards & Advancement

Avillion appoints Ramani Varanasi chief business officer

Thursday, May 30, 2013 01:24 PM

Avillion, which focuses on clinical co-development of therapeutics, has expanded its leadership team, appointing Ramani Varanasi, MSc, MBA, chief business officer.

Varanasi has 18 years of biotechnology and pharmaceutical industry experience  in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions, as well as in business development, management and strategic leadership.


Ramani has held research and senior level positions in business and corporate development  at Merck, Millennium/Takeda, Momenta Pharmaceuticals, Archemix and RXi Pharmaceuticals.

"We are excited to have Ramani on the Avillion team, where our key focus is the execution of co-development and financing deals with pharma and biotech companies,” said Lewis Cameron, CEO of Avillion. “Her experience and leadership in business and corporate development will support Avillion in its goal of establishing partnerships on late-stage clinical assets."
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.